Chronic allograft nephropathy - Clinical guidance for early detection and early intervention strategies

Nephrology Dialysis Transplantation

Volumn 23, Issue 8, 2008, Pages 2467-2473

  Serón, Daniel ^a   Arns, Wolfgang ^b   Chapman, Jeremy R ^c  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

Chronic allograft nephropathy; Everolimus; Proliferation signal inhibitors mammalian target of rapamycin (mTOR) inhibitors; Renal transplantation; Sirolimus

Indexed keywords

CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

CHRONIC ALLOGRAFT NEPHROPATHY; DRUG EFFECT; GLOMERULUS FILTRATION RATE; HUMAN; LOW DRUG DOSE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK FACTOR;

CALCINEURIN; CHRONIC DISEASE; CREATININE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RISK FACTORS; TERMINOLOGY AS TOPIC; TIME FACTORS;

EID: 48749127228     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn130     Document Type: Review

References (82)

1. Meier Kriesche HU, Schold JD, Srinivas TR et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378-383
2. Meier Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies. Am J Transplant 2004; 4: 1289-1295
3. ANZDATA Registry Report. Macdonald S, Chang S, Excell L (eds). Australia and New Zealand Dialysis and Transplantation Registry. Adelaide, Australia: ANZDATA Registry, 2006
4. Pascual M, Theruvath T, Kawai T et al. Strategies to improve long-term outcomes after renal transplantation. New Eng J Med 2002; 346: 580-590
5. Sijpkens YWJ, Doxiadis IIN, de Fijter JW et al. Sharing cross-reactive groups of MHC class I improves long-term graft survival. Kidney Int 1999; 56: 1920-1927
6. Nankivell BJ, Borrows RJ, Fung CL-S et al. The natural history of chronic allograft nephropathy. New Eng J Med 2003; 349: 2326-2333
7. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723
8. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16: 3015-3026
9. Merville P. Combating chronic renal allograft dysfunction: optimal immunosuppressive regimens. Drugs 2005; 65: 615-631
10. Solez K, Colvin RB, Racusen LC et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ("CAN"). Am J Transplant 2007; 7: 518-526
11. Serón D, Moreso F, Fulladosa X et al. Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies. Kidney Int 2002; 61: 727-733
12. Fulladosa X, Moreso F, Torras J et al. Structural and functional correlations in stable renal allografts. Am J Kidney Dis 2003; 41: 1065-1073
13. Nankivell BJ, Borrows RJ, Fung CL-S et al. Evolution and pathophysiology of renal-transplant glomerulosclerosis. Transplantation 2004; 78: 461-468
14. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation 2006; 81: 643-654
15. Kriz W, LeHir M. Pathways to nephron loss starting from glomerular diseases - insights from animal models. Kidney Int 2005; 67: 404-419
16. LeHir M, Kriz W. New insights into structural patterns encountered in glomerulosclerosis. Curr Opin Nephrol Hypertens 2007; 16: 184-191
17. Moreso F, Ibernon M, Gomà M et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006; 6: 747-752
18. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003; 3: 665-673
19. Nankivell BJ, Borrows RJ, Fung CL-S et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004b; 78: 557-565
20. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK506 kidney transplant study group. Transplantation 1998; 66: 1736-1740
21. Chapman JR, Nankivell BJ. Nephrotoxicity of ciclosporin A - short-term gain, long-term pain? Nephrol Dial Transplant 2006; 21: 2060-2063
22. Afzali B, Taylor AL, Goldsmith DJA. What we CAN do about chronic allograft nephropathy: role of immunosuppressive modulations. Kidney Int 2005; 68: 2429-2443
23. Serón D, Moreso F, Ramon JM et al. Protocol renal biopsies and the design of clinical trials aimed to prevent or treat chronic allograft nephropathy. Transplantation 2000; 69: 1849-1855
24. Gonzalez Molina M, Serón D, Garcia del Moral R et al. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy. Transplantation 2004; 77: 215-220
25. Pascual M, Williams WW, Cosimi AB et al. Chronic renal allograft dysfunction: a role for mycophenolate mofetil? Transplantation 2000; 69: 1749-1750
26. Dudley C, Pohanka E, Riad H et al. Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study. Transplantation 2005; 79: 466-475
27. Serón D, Moreso F, Bover J et al. Early protocol renal allograft biopsies and graft outcome. Kidney Int 1997; 51: 310-316
28. Nankivell BJ, Chapman JR. The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant 2006; 6: 2006-2012
29. Dominguez J, Kompatzki A, Noramuena R et al. Benefits of early biopsy on the outcomes of kidney transplantation. Transplant Proc 2005; 37: 3361-3363
30. Furness PN, Taub N, Convergence of European Renal Transplant Pathology Assessment Procedures (CERTPAP) Project. International variation in the interpretation of renal transplant biopsies: report of the CERTPAP Project. Kidney Int 2001; 60: 1998-2012
31. Mengel M, Chapman JR, Cosio FG et al. Protocol biopsies in renal transplantation: insights into patient management and pathogenesis. Am J Transplant 2007; 7: 512-517
32. Kaplan B, Schold J, Meier-Kriesche H-U. Poor predictive value of serum creatinine for renal allograft loss. Am J Transplant 2003; 3: 1560-1565
33. Marqués GG, Goenaga PE, Royo FJL et al. Evolution of the renal function is a better predictor of long-term survival than serum creatinine. Transplant Proc 2005; 37: 3701-3704
34. Raju DL, Grover VK, Shoker A. Limitations of glomerular filtration rate equations in the renal transplant patient. Clin Transplant 2005; 19: 259-268
35. Stevens LA, Coresh J, Greene T et al. Assessing kidney function - measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-2483
36. Esteves FP, Halkar RK, Issa MM et al. Comparison of camera-based 99mTc-MAG and 24-hour creatinine clearances for evaluation of kidney function. Am J Roentgenol 2006; 187: 316-319
37. Meyers CM, Kirk AD. Workshop on late renal allograft dysfunction. Am J Transplant 2005; 5: 1600-1605
38. Sijpkens YWJ, Zwinderman AH, Mallat MJK et al. Intercept and slope analysis of risk factors in chronic renal allograft nephropathy. Graft 2002; 5: 108-113
39. Gaspari F, Ferrari S, Stucchi N et al. Performance of different prediction equations for estimating renal function in kidney transplantation. Am J Transplant 2004; 4: 1826-1835
40. Herget-Rosenthal A, Bokenkamo A, Hofmann W. How to estimate GFR-serum creatinine, serum cystatin C or equations? Clin Biochem 2007; 40: 153-161
41. Schwenger V, Korosoglou G, Hinkel U-P et al. Real-time contrast-enhanced sonography of renal transplant recipients predicts chronic allograft nephropathy. Am J Transplant 2006; 6: 609-615
42. Nankivell BJ, Chapman JR, Grunewald SM. Detection of chronic allograft nephropathy by quantitative Doppler imaging. Transplantation 2002; 74: 90-96
43. Radermacher J, Chavan A, Bleck J et al. Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. N Engl J Med 2001; 344: 410-417
44. Baluja P, Haragsim L, Laszik Z. Chronic allograft nephropathy. Adv Chronic Kidney Dis 2006; 56-61
45. Pascual J. Concentration-controlled everolimus (Certican®): combination with reduced dose calcineurin inhibitors. Transplantation 2005; 79(Suppl 3): S76-S79
46. Oberbauer R, Segoloni G, Campistol JM et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transplant Int 2005; 18: 22-28
47. Kumar MSA, Heifets M, Fyfe B et al. Comparison of four different steroid avoidance protocols in kidney transplantation: tacrolimus (TAC)/mycophenolate mofetil (MMF) versus TAC/sirolimus (SLR) versus cyclosporine (CsA)/MMF versus CsA/SRL. Presented at American Transplant Congress, 2005. Abstract 512
48. Sumethkul V, Changsirikulchai S, Lothuvachai T et al. Sirolimus attenuates the rate of progression of early chronic allograft nephropathy. Transplantation 2006; 82(1 Suppl 2): 517
49. Changsirikulchai S, Chalermsanyakorn P, Watanapokasin R et al. Cyclosporine reduction and sirolimus or mycophenolate mofetil addition attenuate the progressive decline of graft function and stabilize TGF-β1 levels in chronic allograft nephropathy. Transplantation 2006; 82(1 Suppl 2): 507
50. Flechner SM, Kurian SM, Solez K et al. De novo kidney transplantation without the use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 1776-1785
51. Mota A, Arias M, Taskinen EI et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4: 953-961
52. Ruiz JC, Campistol JM, Mota A et al. Early elimination of cyclosporine in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplant Proc 2003; 35: 1669-1670
53. Ruiz JC, Campistol JM, Grinyo JM et al. Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation 2004; 78: 1312-1318
54. Stallone G, Di Paolo S, Schena A et al. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation 2003; 75: 998-1003
55. Fischereder M, Graeb C, Kruger B et al. Conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction. Transplant Proc 2006; 38: 1295-1297
56. Diekmann F, Budde K, Oppenheimer F et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4: 1869-1875
57. Stallone G, Infante B, Schena A et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005; 16: 3755-3762
58. Wali RK, Cooper M, Foster C et al. Early tacrolimus withdrawal and rescue therapy with sirolimus in high-risk renal transplant recipients with moderate to severe chronic allograft nephropathy. Transplantation 2006; 82(1 Suppl 2): 638
59. Ibañez J, Monteverde M, Diaz M et al. Sirolimus effect on chronic allograft dysfunction in pediatric renal recipients. Transplantation 2006; 82(1 Suppl 2): 571
60. Diekmann F, Campistol JM. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks. Nephrol Dial Transplant 2006; 21: 562-568
61. Vitko S, Tedesco H, Eris J et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626-635
62. Tedesco H, Vitko S, Pascual J et al. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transplant Int 2007; 20: 27-36
63. Mulay AV, Hussain N, Fergusson D et al. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systemic review of randomized trials. Am J Transplant 2005; 5: 1748-1756
64. Rapamune® Prescribing Information. Philadelphia, PA: Wyeth Pharmaceuticals Inc., 2006
65. Pascual J, Boletis IN, Campistol JM. Everolimus (Certican®) in renal transplantation: a review of clinical trial data, current usage, and future directions. Transplant Rev 2006; 20: 1-18
66. Serkova N, Litt L, Leibfritz D et al. The novel immunosuppressant SDZ-RAD protects rat brain slices from cyclosporine-induced reduction of high-energy phosphates. Br J Pharmacol 2000; 129: 485-492
67. Serkova N, Jacobsen W, Niemann CU et al. Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain. Br J Pharmacol 2001; 133: 875-885
68. Shihab F, Bennett W, Yi H et al. Comparative effects of sirolimus versus everolimus in similar doses and blood trough levels on chronic cyclosporine nephrotoxicity. Presented at American Transplant Congress, Seattle, WA, USA, 22-24 May, 2005. Abstract 261
69. Abramowicz D, Del Carmen Rial M, Vitko S et al. (Cyclosporine Withdrawal Study Group). Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005; 16: 2234-2240
70. Suwelack B, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004; 4: 655-662
71. Kreis H, Cisterne JM, Land W et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252-1260
72. Larson TS, Dean PG, Stegall MD et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514-522
73. Flechner SM, Goldfarb D, Solez K et al. Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin-inhibitor (CNI) drugs. In: World Transplant Congress, Boston, MA, USA, 22-27 July, 2006. Abstract 749
74. Bellosta S, Arnaboldi L, Canavesi M et al. Fluvastatin modulates the everolimus-induced cholesterol homeostasis in cultured cells. Presented at 26th Annual Meeting of the International Society for Heart and Lung Transplantation, Madrid, April, 2006
75. Granata A, Ferri N, Pirola C et al. In vitro enhanced antiproliferative activity of everolimus on arterial smooth muscle cell by fluvastatin. Presented at 26th Annual Meeting of the International Society for Heart and Lung Transplantation, Madrid, April, 2006
76. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-858
77. Schuurman HJ, Pally C, Weckbecker G et al. SDZ RAD inhibits cold-ischemia-induced vascular remodeling. Transplant Proc 1999; 31: 1024-1025
78. Jolicoeur EM, Qi S, Xu D et al. Combination therapy of mycophenolate mofetil and rapamycin in prevention of chronic renal allograft rejection in the rat. Transplantation 2003; 75: 54-59
79. Koch M, Mengel M, Poehnert D et al. Effects of everolimus on cellular and humoral immune processes leading to chronic allograft nephropathy in a rat model with sensitized recipients. Transplantation 2007; 83: 498-505
80. Lutz J, Zou H, Liu S et al. Apoptosis and treatment of chronic allograft nephropathy with everolimus. Transplantation 2003, 76: 508-515
81. Roos M, Lutz J, Strobl M et al. Monotherapy with everolimus or FTY720 ameliorates chronic allograft nephropathy (CAN) at late stages, while the combination with cyclosporine does not treat CAN. Transplantation 2006; 82(1 Suppl 2): 885
82. Gregory CR, Huang X, Pratt RE et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995; 59: 655-661